NGM Bio to Host the First of Four Virtual R&D Events on March 30, 2022
March 21 2022 - 8:00AM
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a
biotechnology company focused on discovering and developing
transformative therapeutics for patients, today announced it will
host the first of four virtual R&D events on Wednesday, March
30, 2022, from 11:00 am – 12:15 pm ET. This four-part series of
virtual webcasts, titled the “Explorer Series”, will highlight the
company’s work as explorers on the frontier of life-changing
science.
The first event will focus on NGM Bio’s highly productive
discovery engine which has generated NGM Bio’s entire pipeline of
therapeutic candidates. The program will feature presentations from
David Woodhouse, Ph.D., Chief Executive Officer and Jin-Long Chen,
Ph.D., Founder and Chief Scientific Officer as well as multiple
members of NGM Bio’s biology, biologics, and translational teams.
During the presentations, NGM Bio will introduce a previously
undisclosed preclinical program as a new example of its discovery
engine in action.
Future sessions will cover four NGM Bio-discovered programs –
NGM707 (a dual ILT2/ILT4 antagonist antibody product candidate),
NGM831 (an ILT3 antagonist antibody product candidate), NGM438 (a
LAIR1 antagonist antibody product candidate) and NGM621 (an anti-
complement C3 antibody product candidate). Each session will
feature members from NGM Bio’s management and scientific team as
well as leading industry physicians and scientists.
A live webcast of the presentation will be available under the
Investors and Media section of NGM Bio’s website at
https://ir.ngmbio.com/events-presentations. A replay of the webcast
will be archived on NGM Bio’s site for one year following the
event.
To register for the event, please visit this link.
About NGM Bio
NGM Bio is focused on discovering and developing novel,
life-changing medicines for people whose health and lives have been
disrupted by disease. The company’s biology-centric drug discovery
approach aims
to seamlessly integrate interrogation of complex
disease-associated biology and protein engineering expertise to
unlock proprietary insights that are leveraged to generate
promising product candidates and enable their rapid advancement
into proof-of-concept studies. As explorers on the frontier of
life-changing science, NGM Bio aspires to operate one of the most
productive research and development engines in the
biopharmaceutical industry. All therapeutic candidates in the NGM
Bio pipeline have been generated by its in-house discovery engine,
with a disease-agnostic mindset, always led by biology and
motivated by unmet patient need. Today, the company has seven
disclosed programs, including four in Phase 2 or 2b
studies, across three therapeutic areas:
cancer, retinal diseases and liver and
metabolic diseases. Visit us at www.ngmbio.com for more
information.
Investor
Contact:Brian Schoelkopfir@ngmbio.com |
Media
Contact:media@ngmbio.com |
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Sep 2024 to Oct 2024
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Oct 2023 to Oct 2024